Imaging devices fail to pick up RNFL defects

Article

Various imaging devices fail to identify localized retinal nerve fibre layer (RNFL) defects, according to a study published in the January issue of the British Journal of Ophthalmology.

Various imaging devices fail to identify localized retinal nerve fibre layer (RNFL) defects, according to a study published in the January issue of the British Journal of Ophthalmology.

Dr M T Nicolela of the Eye Care Center, Nova Scotia, Canada and colleagues had three masked observers assess eyes (51 with RNFL defects visible on optic disc photographs and 51 control) with confocal scanning laser tomography (CSLT), scanning laser polarimetry (SLP) and optical coherence tomography (OCT) to establish which device provided a more accurate image of localized damage.

The observers had the greatest degree of agreement of RNFL defect as displayed on OCT (kappa, 0.83), followed by SLP (0.69) and CSLT (0.64). At least two oberserves identified RNFL defects in 58.8%, 66.7% and 54.9% of images from CSLT, SLP and OCT, respectively. With CSLT, SLP and OCT, the observers rated 94.1%, 84.3% and 94.1%, respectively, of control eyes as normal.

The researchers deduced that between 20% and 40% of RNFL defects shown on colour optic disc photographs fail to be identified by CSLT, SPL or OCT. Of all three methods, SLP had the highest rate of both false-positives and correct RNFL defect identification.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.